Motus GI Holdings, Inc. · OTC:MOTS
Motus GI — Investor Presentation (June 2018)
24 slides from Motus GI's investor presentation, Jun 4, 2018
Slide 1: Developing Breakthrough Solutions for Endoscopy
Developing Breakthrough Solutions for Endoscopy June 2018 NASDAQ: MOTS www.motusgi.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” including those relating to the Company’s product development, “potential,” “predict,” “project,” “should,” “would” and similar clinical studies,
Slide 3: Developing Breakthrough Solutions for GI Endoscopy
Developing Breakthrough Solutions for GI Endoscopy FDA Cleared Flagship Product, Pure Vu® System, Enables Rapid Bowel Cleansing During Colonoscopy Procedures Targeting multi billion dollar market opportunity Leveraging existing hospital reimbursement (DRG) Developing key clinical and health economic
Slide 4: Targeting Multi-Billion Dollar Market Opportunities
Targeting Multi-Billion Dollar Market Opportunities Current Focus Inpatient: Lower GI Colonoscopy 3.8M 1 Value: Lower costs, speed diagnosis, DRG-based reimbursement Worldwide Procedures Annually Expansion Opportunities Inpatient: Upper GI Bleed Endoscopy 1M 2 Value: Removes clots and debris to prov
Slide 5: Pure-Vu video
PURE-VLU' » MOTUS” PLAY VIDEO >
Slide 6: Pure-Vu Overview
Pure-Vu® Overview Disposable Workstation Sleeve on Scope Integrates easily with current scopes and physician workflow Highly effective pulsed vortex irrigation to break up colon content Efficient evacuation with anti clogging Auto Purge technology Standard Strong intellectual property colonoscope Ir
Slide 7: Clinical Results Indicate Outstanding Cleaning Performance
Clinical Results Indicate Outstanding Cleaning Performance Reduced Prep: ~18 Hour Full Liquid Diet and Dulcolax® % of Subjects Adequately Prepped Boston Bowel Preparation Scale (BBPS) According to BBPS Standard 1 Score Pre and Post Pure-Vu® 100% 100.0% Pure-Vu® Study Pre PV Post PV 98.0% 90% Multice
Slide 8: Inpatient Colonoscopy Procedures
Inpatient Colonoscopy Procedures 3.8M Worldwide Patients Annually 1 Lower Severe Unknown Spinal Cord GI Bleeds Anemia Abdominal Pain Injury (VA) ER, ICU and Bowel Prep and Procedure Successful Exam and Hospital Ward Take Place in Hospital Patient Discharged Fixed bundled payments cover entire episod
Slide 9: Bowel Prep Challenges Represent Significant Burden
Bowel Prep Challenges Represent Significant Burden Insufficient bowel prep leads to frequent delays, procedure failures and increased costs 55% Occupied Bed Inpatient 24 Hour Repeat Repeat Insufficiently Not Available for Colonoscopy Bowel Prep Bowel Prep Procedures Prepped 1 New Patients ~2 days lo
Slide 10: Potential to Reduce Direct Costs for Inpatient Colonoscopy
Potential to Reduce Direct Costs for Inpatient Colonoscopy Potential to become new standard of care Accelerated Bed Inpatient Turn-over for Colonoscopy New Patients Pure-Vu® has the potential to: Reduce time to successful bowel prep Eliminate repeat procedures Improve quality of exam and diagnosis R
Slide 11: REDUCE Study
REDUCE Study Targeted Completion in Q4 2018 Currently Enrolling Patients 100 Patient, single-arm, multi-center, prospective study Enables First Time Procedure Success 55% Accelerated Bed Inpatient 24 Hour Repeat Repeat Insufficiently Turn-over for Colonoscopy Bowel Prep Bowel Prep Procedures Prepped
Slide 12: Lower GI Bleed Study
Lower GI Bleed Study Expected to Initiate 2 nd Half 2018 Feasibility study to accelerate time to procedure Shorten Time to Colonoscopy Procedure and Diagnosis Emergent 55% Accelerated Bed Lower GI Bleed 24 Hour Repeat Repeat Insufficiently Turn-over for Bowel Prep Bowel Prep Procedures Patient Prepp
Slide 13: Driving Cost Savings to Support Value Based Pricing
Driving Cost Savings to Support Value Based Pricing Potential direct hospital cost savings based on shortened length of stay* ~$2,000 per patient in US 1 ~$1,000 per patient in key OUS markets 2 Prospective value based pricing Disposable ASP: $500-$1,000 Workstation ASP: $40K-$80K ~$5.3 Billion 1,2
Slide 14: Inpatient Expansion Opportunity
Inpatient Expansion Opportunity Market Opportunity Inpatient: Upper GI Bleed Endoscopy Value: 1M 1 Remove clots and debris to provide clear field of view Worldwide Leverage existing hospital call points, doctors and sales force Procedures Annually Potential Product Launch in 2020 2 14 1: El-Tawil AM
Slide 15: Outpatient Expansion Opportunity
Outpatient Expansion Opportunity Outpatient: High Medical Need/Difficult to Prep Colonoscopy Market Opportunity Value: ~23% of patients present with an inadequately prepped colon 1 5.7M 2 Eliminate repeat procedures, improves diagnosis Worldwide Procedures Annually Leverage existing product and hosp
Slide 16: Commercialization Timeline 2018 to Beyond
5.7M 1 Worldwide HMN / Inadequate Prep Colonoscopy Procedures Annually 1M 2 Worldwide Upper GI Bleed Endoscopy Procedures Annually 3.8M 3 Worldwide Inpatient Colonoscopy Procedures Annually 2018 2019 2020 - 2021 Beyond Market Development Commercial Introduction Commercial Growth Commercial Expansion
Slide 17: Robust Intellectual Property Covers Innovative Portfolio of Technologies
Robust Intellectual Property Covers Innovative Portfolio of Technologies Rooted in Systems and Methods for Cleaning Body Cavities With or Without the Use of Endoscope 7 10 18 Issued patents in Pending patents Pending United States, in United States patents outside Europe and Asia United States 17
Slide 18: Financial Profile
Market Cap: $92M 1 Common Shares Outstanding: ~15.6M Financial Profile: NASDAQ: MOTS Average Daily Volume: ~57K 1 Cash Balance: ~$18.6M 2 1: Based on June 1, 2018 closing price of $5.88 per share 18 2: As of March 31, 2018
Slide 19: Management Team
Management Team Mark Pomeranz, Chief Executive Officer Andrew L. Taylor, MBA, Chief Financial Hagit Ephrath, VP, Clinical Regulatory Officer and Health Economics 30 years of experience in the medical device Over 20 years of experience serving as a Nearly 20 years of medical device experience industr
Slide 20: Board of Directors
Board of Directors David Hochman Gary Jacobs Shervin Korangy Samuel Nussbaum Chairman Director of Corbus, Adgero, Managing Director, Jacobs CFO and Chief Strategy Officer of Former EVP, Clinical Health Policy Caliber, and BackBeat; Managing Investment Company Beaver-Visitec International & CMO of An
Slide 21: Physician Advisory Board
Physician Advisory Board Gerald Bertiger, MD Steven A. Edmundowicz, MD, Prof. Ian Gralnek, MD, MSHS, Seth A. Gross, MD, FACG, FASGE FASGE FASGE, AGAF Managing Partner and President of Medical Director, Digestive Health Chief, Ellen and Pinchas Mamber Associate Professor of Medicine, Hillmont, GI, P.
Slide 22: Near Term Value Catalysts
Near Term Value Catalysts Secured Initiate Launch Complete Financing REDUCE Study Multiple Studies REDUCE Study Public Offering Medical Advisory Initiate lower GI bleed Complete REDUCE Board Appointment inpatient study inpatient study Pure-Vu® CE mark approval Initiate REDUCE Initiate high medical P
Slide 23: Revolutionizing the large and growing GI endoscopy market
Revolutionizing the large and growing GI endoscopy market Inpatient market represents multi-billion dollar opportunity Investment Building a strong foundation of clinical and health economic data Highlights Opportunity to become standard of care in key endoscopy segments Highly-experienced managemen
Slide 24: Thank you
Thank you info@motusgi.com NASDAQ: MOTS www.motusgi.com
Motus GI Holdings — Investor Presentation (June 2018) on 6ix